Barclays raised the firm’s price target on CVS Health (CVS) to $93 from $87 and keeps an Overweight rating on the shares following the investor day. The company guided to mid-teens earnings growth through 2028, which includes margin improvement at Aetna and Care Delivery, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health price target raised to $97 from $96 at UBS
- CVS Health: Strong Financial Outlook and Strategic Initiatives Drive Buy Rating
- CVS Health’s Promising Growth Trajectory and Strategic Focus Drive Buy Rating
- CVS Health: Strategic Initiatives and Financial Outlook Drive Buy Rating
- CVS Health: Projected Growth and Strategic Capital Deployment Drive Buy Rating